GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » EV-to-Revenue

Biogen (BSP:BIIB34) EV-to-Revenue

: 3.81 (As of Today)
View and export this data going back to 2016. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biogen's enterprise value is R$186,278 Mil. Biogen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was R$48,938 Mil. Therefore, Biogen's EV-to-Revenue for today is 3.81.

The historical rank and industry rank for Biogen's EV-to-Revenue or its related term are showing as below:

BSP:BIIB34' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.95   Med: 4.92   Max: 10.87
Current: 3.47

During the past 13 years, the highest EV-to-Revenue of Biogen was 10.87. The lowest was 2.95. And the median was 4.92.

BSP:BIIB34's EV-to-Revenue is ranked worse than
67.74% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.33 vs BSP:BIIB34: 3.47

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-18), Biogen's stock price is R$175.14. Biogen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was R$55.90. Therefore, Biogen's PS Ratio for today is 3.13.


Biogen EV-to-Revenue Historical Data

The historical data trend for Biogen's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 3.16 3.56 4.09 4.45

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.09 4.14 4.19 4.27 4.45

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biogen's EV-to-Revenue falls into.



Biogen EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biogen's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=186278.394/48938.255
=3.81

Biogen's current Enterprise Value is R$186,278 Mil.
Biogen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$48,938 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BSP:BIIB34) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biogen's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=175.14/55.896
=3.13

Biogen's share price for today is R$175.14.
Biogen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$55.90.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biogen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BSP:BIIB34) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines